ZYNRELEF Market Drug Insight

“ZYNRELEF Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ZYNRELEF for Postoperative Pain and Acute Pain in the 7MM. A detailed picture of the ZYNRELEF in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report, along with a detailed description of the ZYNRELEF. The UPLIZNA Market Report provides insight about UPLIZNA Mechanism of Action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNRELEF Market Forecast, analysis in the 7MM, descriptive analysis such as SWOT, analyst views, a comprehensive overview of market competitors, and a brief about emerging therapies.

UPLIZNA Drug Summary

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) is a fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. The drug is approved in Europe, while an NDA in the US has been resubmitted. ZYNRELEF is indicated to treat somatic-postoperative pain from small- to medium-sized surgical wounds in adults. Efficacy and safety have not been established in major surgeries, including abdominal, vascular and thoracic surgeries. The drug is designed to deliver superior pain relief while reducing the need for systemically administered pain medications, such as opioids. The inclusion of low-dose meloxicam in the drug reduces local inflammation and reverses the acidic environment caused by surgery, allowing enhanced penetration of bupivacaine into the nerves and thereby potentiating its effect.

ZYNRELEF is a fixed-dose, prolonged-release combination of bupivacaine and meloxicam. For approximately 72 h after ZYNRELEF is applied to the surgical site, it releases bupivacaine and meloxicam, which are then absorbed into the surrounding tissues. Meloxicam is believed to control tissue inflammation, thereby normalizing the pH and potentiating the effect of bupivacaine, increasing analgesia. The company anticipates the availability of ZYNRELEF to patients in Europe during 2022. Each mL of solution contains 29.25 mg of bupivacaine and 0.88 mg of meloxicam. Each vial delivers a dose of 60 mg/1.8 mg of bupivacaine/meloxicam. The maximum total dose of ZYNRELEF to be applied not recommended to exceed 400 mg/12 mg (about 14 mL). Bupivacaine is a local anesthetic that temporarily numbs the area to which it has been applied by blocking pain signals to the brain. Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), reduces pain and inflammation and strengthens the effect of bupivacaine.

UPLIZNA Market Forecast Report Scope

The report provides insights into:

• A comprehensive product overview including the ZYNRELEF description, UPLIZNA Mechanism of Action, dosage and administration, research and development activities in postoperative pain and acute pain.
• Elaborated details on ZYNRELEF regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZYNRELEF research and development activity in postoperative pain and acute pain details across the United States, Europe, and Japan.
• The UPLIZNA Market Size Report also covers the patent information with expiry timeline around ZYNRELEF.
• The report contains forecasted UPLIZNA Sales for postoperative pain and acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for postoperative pain and acute pain.
• The UPLIZNA Market Size Report also features the SWOT analysis with analyst views for ZYNRELEF in postoperative pain and acute pain.

UPLIZNA Methodology

The UPLIZNA Market Size Report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight’s team of industry experts. Information and UPLIZNA Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

ZYNRELEF Market Analytical Perspective by DelveInsight

• In-depth ZYNRELEF Market Assessment

This report provides a detailed market assessment of ZYNRELEF in postoperative pain and acute pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted UPLIZNA Sales Data from 2022 to 2032.

• ZYNRELEF Clinical Trials Assessment

The report provides the UPLIZNA Clinical Trials information for postoperative pain and acute pain, covering trial interventions, trial conditions, trial status, start, and completion dates.

UPLIZNA Market Forecast Report Highlights 

• In the coming years, the UPLIZNA Market scenario for postoperative pain and acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug UPLIZNA Manufacturers to penetrate more into the market.  
• The UPLIZNA Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNRELEF dominance.
• Other emerging products for postoperative pain and acute pain are expected to give tough market competition to ZYNRELEF and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of ZYNRELEF in postoperative pain and acute pain.
• Our in-depth analysis of the forecasted sales data of ZYNRELEF from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZYNRELEF in postoperative pain and acute pain.
• Analyze UPLIZNA Cost, pricing trends, and market positioning to support strategic decision-making in the UPLIZNA Market Landscape.

Key Questions

• What is the UPLIZNA Product Type, route of administration, and UPLIZNA Mechanism of Action?
• What is the UPLIZNA Clinical Trials status of the study related to postoperative pain and acute pain, and the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the ZYNRELEF development?
• What are the key designations that have been granted to ZYNRELEF for postoperative pain and acute pain?
• What is the forecasted market scenario of ZYNRELEF for postoperative pain and acute pain?
• What are the forecasted ZYNRELEF Sales in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging UPLIZNA Products available in postoperative pain and acute pain, and how are they giving competition to ZYNRELEF for postoperative pain and acute pain?
• Which are the late-stage emerging therapies under development for the treatment of postoperative pain and acute pain?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs